Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu Mi Kang

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Endocrinology and Metabolism (Seoul, Korea)|September 29, 2017
Effects of Incretin-Based Therapies on Diabetic Microvascular ComplicationsYu Mi Kang, Chang Hee Jung
The Lancet. Diabetes & Endocrinology|April 20, 2026
What REDEFINE 5 signals for obesity trials in Asia and beyondYu Mi Kang, Vanita R Aroda
Endocrinology and Metabolism (Seoul, Korea)|April 28, 2016
Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor AgonistsYu Mi Kang, Chang Hee Jung
Diabetes Care|October 21, 2024
Is This the Real Life? Real-World Evidence of Empagliflozin in Health Care Resource Utilization and CostJosephine Harrington, Yu Mi Kang, Darren K McGuire
Diabetes & Metabolism Journal|April 28, 2017
Role of NO/VASP Signaling Pathway against Obesity-Related Inflammation and Insulin ResistanceYu Mi Kang, Francis Kim, Woo Je Lee
Radiation Research|August 24, 2010
Life span and thymic lymphoma incidence in high- and low-dose-rate irradiated AKR/J mice and commonly expressed genesSuk Chul Shin, Yu Mi Kang, Hee Sun Kim
Expert Opinion on Pharmacotherapy|May 9, 2025
The contemporary landscape of cardiovascular optimization in type 2 diabetes: overcoming barriers to evidence-based use of newer antihyperglycemic agentsKareem Malas, Salman Kazmi, Yu Mi Kang, et al.
Diabetes, Obesity & Metabolism|February 27, 2026
Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and VomitingMichael A Nauck, Viktoria Punov, Yu Mi Kang, et al.
Diabetes, Obesity & Metabolism|April 11, 2025
Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trialsYu Mi Kang, Viktoria Punov, Soo Lim, et al.
BMC Pulmonary Medicine|May 7, 2021
Exploring the impact of number and type of comorbidities on the risk of severe COPD exacerbations in Korean Population: a Nationwide Cohort StudyYoungmee Kim, Ye-Jee Kim, Yu Mi Kang, et al.
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Endocrinology and Metabolism (Seoul, Korea)|September 29, 2017
Effects of Incretin-Based Therapies on Diabetic Microvascular ComplicationsYu Mi Kang, Chang Hee Jung
The Lancet. Diabetes & Endocrinology|April 20, 2026
What REDEFINE 5 signals for obesity trials in Asia and beyondYu Mi Kang, Vanita R Aroda
Endocrinology and Metabolism (Seoul, Korea)|April 28, 2016
Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor AgonistsYu Mi Kang, Chang Hee Jung
Diabetes Care|October 21, 2024
Is This the Real Life? Real-World Evidence of Empagliflozin in Health Care Resource Utilization and CostJosephine Harrington, Yu Mi Kang, Darren K McGuire
Diabetes & Metabolism Journal|April 28, 2017
Role of NO/VASP Signaling Pathway against Obesity-Related Inflammation and Insulin ResistanceYu Mi Kang, Francis Kim, Woo Je Lee
Radiation Research|August 24, 2010
Life span and thymic lymphoma incidence in high- and low-dose-rate irradiated AKR/J mice and commonly expressed genesSuk Chul Shin, Yu Mi Kang, Hee Sun Kim
Expert Opinion on Pharmacotherapy|May 9, 2025
The contemporary landscape of cardiovascular optimization in type 2 diabetes: overcoming barriers to evidence-based use of newer antihyperglycemic agentsKareem Malas, Salman Kazmi, Yu Mi Kang, et al.
Diabetes, Obesity & Metabolism|February 27, 2026
Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and VomitingMichael A Nauck, Viktoria Punov, Yu Mi Kang, et al.
Diabetes, Obesity & Metabolism|April 11, 2025
Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trialsYu Mi Kang, Viktoria Punov, Soo Lim, et al.
BMC Pulmonary Medicine|May 7, 2021
Exploring the impact of number and type of comorbidities on the risk of severe COPD exacerbations in Korean Population: a Nationwide Cohort StudyYoungmee Kim, Ye-Jee Kim, Yu Mi Kang, et al.
Pageof 7